3SBio (HKG:1530) Has Announced A Dividend Of CN¥0.25

3SBio Inc. (HKG:1530) will pay a dividend of CN¥0.25 on the 15th of August. This means that the annual payment will be 2.1% of the current stock price, which is in line with the average for the industry.

While the dividend yield is important for income investors, it is also important to consider any large share price moves, as this will generally outweigh any gains from distributions. Investors will be pleased to see that 3SBio's stock price has increased by 93% in the last 3 months, which is good for shareholders and can also explain a decrease in the dividend yield.

Advertisement

3SBio's Payment Could Potentially Have Solid Earnings Coverage

While it is always good to see a solid dividend yield, we should also consider whether the payment is feasible. However, 3SBio's earnings easily cover the dividend. This means that most of its earnings are being retained to grow the business.

Looking forward, earnings per share is forecast to rise by 43.8% over the next year. Assuming the dividend continues along recent trends, we think the payout ratio could be 23% by next year, which is in a pretty sustainable range.

historic-dividend
SEHK:1530 Historic Dividend April 17th 2025

View our latest analysis for 3SBio

3SBio's Dividend Has Lacked Consistency

It's comforting to see that 3SBio has been paying a dividend for a number of years now, however it has been cut at least once in that time. This makes us cautious about the consistency of the dividend over a full economic cycle. Since 2018, the annual payment back then was CN¥0.0547, compared to the most recent full-year payment of CN¥0.233. This implies that the company grew its distributions at a yearly rate of about 23% over that duration. 3SBio has grown distributions at a rapid rate despite cutting the dividend at least once in the past. Companies that cut once often cut again, so we would be cautious about buying this stock solely for the dividend income.

The Dividend Looks Likely To Grow

Given that the dividend has been cut in the past, we need to check if earnings are growing and if that might lead to stronger dividends in the future. We are encouraged to see that 3SBio has grown earnings per share at 18% per year over the past five years. Growth in EPS bodes well for the dividend, as does the low payout ratio that the company is currently reporting.

We Really Like 3SBio's Dividend

Overall, we think that this is a great income investment, and we think that maintaining the dividend this year may have been a conservative choice. Earnings are easily covering distributions, and the company is generating plenty of cash. All in all, this checks a lot of the boxes we look for when choosing an income stock.

Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. For instance, we've picked out 1 warning sign for 3SBio that investors should take into consideration. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.

Valuation is complex, but we're here to simplify it.

Discover if 3SBio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:1530

3SBio

An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.

Outstanding track record with flawless balance sheet.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0768.0% undervalued
284 users have followed this narrative
1 users have commented on this narrative
41 users have liked this narrative
GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.3% undervalued
93 users have followed this narrative
1 users have commented on this narrative
23 users have liked this narrative
TO
Tokyo
ABI logo
Tokyo on Anheuser-Busch InBev ·

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

Fair Value:€89.4524.2% undervalued
7 users have followed this narrative
3 users have commented on this narrative
3 users have liked this narrative
OS
oscargarcia
AMZN logo
oscargarcia on Amazon.com ·

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.

Fair Value:US$2803.2% undervalued
62 users have followed this narrative
1 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

HU
MBRIGHT logo
Hunter_Z on Meta Bright Group Berhad ·

Meta Bright’s Bumidotearth Move: A Small Acquisition With Bigger Strategic Implications

Fair Value:RM 0.569.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
SMR logo
AndrewHabib on NuScale Power ·

NuScale Power will achieve impressive revenue growth if Entra1 can deliver

Fair Value:US$13.537.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TA
Talos
EVAX logo
Talos on Evaxion ·

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Fair Value:US$20.2579.9% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.3% undervalued
93 users have followed this narrative
1 users have commented on this narrative
23 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.230.7% undervalued
68 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9325.1% undervalued
1397 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative